Latest Blog
Snowfish Blog
-
Now that the merger between CVS Health and Aetna is final, there is no better time to update our prior article which provided some interesting tidbits about the retail clinic business. There is no doubt that this marriage of two health care behemoths will generate a lot of upheaval in the public domain. Many stakeholders
Details -
Welcome to the second post based on the Axios program Beyond 2020: Making Care Affordable featuring leading administration, legislative, and industry stakeholders. The goal of this program was to inspire thought on how best to manage the costs of prescription therapies. The first article in this series delved into the topic of the cost of new
Details -
Scott Gottlieb, MD being interviewed by Axios’ Bob Herman. A jam-packed hour contemplating the future of health care, just another morning in DC. The Snowfish team heard leading administration, legislative, and industry stakeholders opine on the topic of Beyond 2020: Making Care Affordable, hosted by Axios. On the docket were Scott Gottlieb, MD Former FDA
Details -
Around two decades ago, key opinion leader (KOL) identification and mapping was a bleeding edge concept. Hard to fathom but at the time, therapeutics companies were using word-of-mouth, sales force recommendations, and even publications alone as a primary means for identifying the thought leaders in a given disease state area. Using an analytical approach for
Details -
The recent approval of CVS Health’s merger with Aetna is being heralded as nothing less than potentially “transformational” to the health care system. Innovative ideas to streamline care and encourage cost effectiveness are not new. This is illustrated by the undefined collaboration between Amazon, Berkshire Hathaway and JP Morgan. Nevertheless here is the joining of the consumers,
Details -
Patient recruitment is a critical component for drug development. A troubling statistic from the National Institutes of Health (NIH) reports that more than 80% of clinical trials in the United States (U.S.) fail to meet their patient recruitment timelines. This despite that 30% U.S. pharmaceutical industry’s time dedicated to clinical trials is spent on patient recruitment and enrollment.
Details -
Getting to the source of all that ails you! No side effects! Learn all about it while having a great meal! When one thinks of seminar on stem cell therapy, this is not necessarily what comes to mind. Rather the visual is a scientific symposium in which scientists enthusiastically remark on well-cited studies and hypothesize
Details -
The Centers for Medicare and Medicaid Services, CMS, recently released the latest 2017 Open Payments data, providing now a total of over four years of pharma payment data for analysis. The total database now contains details of over 74 million payments to nearly one million physicians and over four thousand hospitals. A lot can be learned about overall
Details -
Cannabis as medicine, while unregulated A few months ago, I planned an outing to the Trans-Allegheny Lunatic Asylum in West Virginia. I know it is an odd place to visit but I enjoy all types of history, including medically-related. The facility opened in 1864 and reached its peak in the 1950’s, housing 2,400 patients. Changes in the
Details -
Singer Elvis Costello was just forced to cancel his tour to recover from surgery that he underwent to treat cancer. We wish him the best for a full recovery. While termed as “very aggressive”, news reports have noted that it his tumor is small and should be “defeated” through this single procedure. At this time, it
Details